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Brazilian Guidelines to HCV treatment (2007) recommended that the first choice treatment for patients 
with chronic hepatitis C (CHC) and genotype 2 or 3 is interferon alpha (IFN) plus ribavirin (RBV) for 
24 weeks. The aim of this study is compare the cost and effectiveness to Hepatitis C treatment in patients 
with genotype 2 or 3 of peginterferon alpha (PEG) as the first choice of treatment within PEG for those 
that do not respond to IFN. The target population is CHC patients with genotype 2 or 3 in Brazil. The 
interventions are: PEG-SEC (first IFN plus RBV for 24 weeks, after, for non-responders and relapsers 
subsequently PEG plus RBV for 48 weeks); PEG-FIRST24 (PEG+RBV for 24 weeks). The type of the 
study is cost-effectiveness analysis. The data sources are: Effectiveness data from meta-analysis conducted 
on the Brazilian population. Treatment cost from Brazilian micro costing study is converted into USD 
(2010). The perspective is the Public Health System. The outcome measurements are Sustained Viral 
Response (SVR) and costs. PEG-FIRST24 (SVR: 87.8%, costs: USD 8,338.27) was more effective and 
more costly than PEG-SEC (SVR: 79.2%, costs: USD 5,852.99). The sensitivity analyses are: When 
SVR rates with IFN was less than 30% PEG-FIRST is dominant. On the other hand, when SVR with 
IFN was more then 75% PEG-SEC is dominant (SVR=88.2% and costs USD $ 3,753.00). PEG-SEC 
is also dominant when SVR to PEG24 weeks was less than 54%. In the Brazilian context, PEG-FIRST 
is more effective and more expensive than PEG-SEC. PEG-SEC could be dominant when rates of IFN 
therapy are higher than 75% or rates of PEG24 therapy are lower than 54%.
Uniterms: Hepatitis C chronic/treatment. Interferon alpha/Hepatitis C treatment. Ribavirin/Hepatitis C 
treatment. Peginterferon alpha/Hepatitis C treatment. Hepatitis C/ treatment/cost-effectiveness evaluation.
O protocolo brasileiro de tratamento da Hepatite C (2007) recomendava como primeira escolha para 
pacientes com hepatite C crônica e portadores de genótipo 2 ou 3 o tratamento com interferona alfa 
(IFN) associada à ribavirina (RBV), por 24 semanas. O objetivo deste estudo é comparar o custo e a 
efetividade para pacientes com hepatite C crônica e portadores do genótipo 2 ou 3 o uso de peguinterferon 
(PEG) como primeiro escolha com o PEG como secunda escolha para aqueles que não responderam 
ao tratamento com IFN. A população alvo compreende pacientes com hepatite C crônica portadores de 
genótipo 2 ou 3 no Brasil. As intervenções são: PEG-SEC (IFN + RBV por 24 semanas, para os não 
respondedores e recidivantes tratamento subsequente com PEG + RBV por 48 semanas; PEG-FIRST24 
(PEG + RBV por 24 semanas). O tipo de estudo envolvido é Análise de Custo Efetividade. Os dados de 
efetividade são provenientes de um metanálise de estudos brasileiros e os dados de custo do tratamento 
de um estudo de custo do contexto brasileiro. A perspectiva é o Sistema Público de Saúde. Os desfechos 
avaliados foram Resposta Viral Sustentada (RVS) e Custos. PEG-FIRST24 (RVS: 87,8%, costs: USD 
8.338,27) foi mais efetivo e apresentou maior custo que PEG-SEC (RVS: 79,2%, custo USD 5.852,99). 
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A análise de sensibilidade demonstrou que PEG-SEC é dominado por PEG-FIRST24 quando RVS com 
IFN for menor que 30%. Por outro lado, quando RVS com IFN for maior que 75% PEG-SEC é dominante 
(RVS=88.2% e custo USD $ 3.753,00). PEG-SEC é também dominante quando RVS para PEG24 for 
menor que 54%. Conclusão: No contexto brasileiro, PEG-FIRST é mais efetivo e mais custoso que 
PEG-SEC. PEG-SEC poderia ser dominante quando as taxas de RVS do tratamento com IFN forem 
superiores a 75% ou as taxas de PEG24 forem inferiores a 54%.
Unitermos: Hepatite C crônica/tratamento. Interferona alfa/tratamento da hepatite C. Ribavirin/
tratamento da hepatite C. Peginterferona alfa/tratamento da hepatite C. Hepatitis C/tratamento/análise 
de custo-efetividade.
INTRODUCTION
The prevalence of Chronic Hepatitis C (CHC) varies 
widely, depending on geographic region and exposure 
to secondary risk factors. In Brazil the prevalence was 
estimated at 2.5% among adults. Most of the prevalence 
studies focused on specific subsets of the population, 
which could not be used for extrapolative purposes 
(Kershenobich et al., 2011). The Brazilian Ministry 
of Health is carrying out a population-based survey to 
provide information on the prevalence of hepatitis viral 
infections, where the pattern of risk factors was considered 
in the urban population of all Brazilian state capitals and 
the Federal District, between 2005 and 2009 (Ximenes et 
al., 2010). Preliminary data suggests that the prevalence 
of hepatitis C ranges from 0.9% to 1.9% (Brazil, 2010).
A Brazilian study assessed 1,688 HCV patients from 
multiple regions and reported the following genotype 
distribution: genotype 1 (64.9%), genotype 2 (4.6%), 
genotype 3 (30.2%) and genotype 4 (0.2%) (Campiotto 
et al., 2005).
Progression to chronic hepatitis C occurs in at least 
80% of patients with acute HCV infection, and cirrhosis 
develops in 20-30% of these individuals (Shepherd et 
al., 2007). The evolution of the illness is associated 
with the development of cirrhosis, liver insufficiency 
or hepatocellular carcinoma, the leading cause of liver 
transplantation in adults (Seeff, 2009).
According to  a  nat ional  survey to  update 
hepatocellular carcinoma epidemiology in Brazil, 
encompassing 29 centers and 1,405 patients and carried 
out from 2004 to 2009, hepatitis C infection was found to 
be the most common etiology of liver cirrhosis and liver 
cirrhosis was the main risk factor for HCC development 
in Brazil (Carrilho et al., 2010). The management of 
HCV infection is one of the most important current health 
concerns because of the high risk of chronic infection and 
the lack of a suitable vaccine.
In beginning of HCV treatment the most effective 
initial therapy for patients with hepatitis C was the 
combination of interferon alpha (IFN) with ribavirin 
(RBV) (Poynard et al., 1998; Mchutchison, 1999). 
Recently, there has been a modification of interferon alpha 
with the addition of a polyethylene glycol molecule to 
interferon (PEG) in order to produce a biologically active 
molecule with a longer half-life than the natural molecule. 
More favorable pharmacokinetics and its characteristics 
allow for weekly dose administration which is more 
convenient (Manns et al., 2001).
The results from clinical trials indicate that HCV 
genotype 1 have better rates of sustained viral response 
(SVR) using peginterferon alpha (PEG) plus RBV 
compared to IFN plus RBV (SVR for PEG alpha-2a 
combination therapy were 46%, compared with 36% for 
interferon alpha-2a combination therapy). But for genotype 
2 or 3 the rates of SVR do not have statistical significance 
in either treatment. When the PEG alpha-2b and interferon 
alpha-2b combination therapies were compared, the SVR 
values were 82% and 79% respectively, on an intention-
to-treat basis (Manns et al., 2001; Nice, 2004; Shepherd 
et al., 2007; Nice, 2010).
In many countries like the United Kingdom, Austria, 
Canada and Sweden, regardless of genotype, the preferred 
treatment regimen is a combination of PEG 2a or 2b, 
administered subcutaneously once a week, with RBV 
taken orally daily in two doses. The duration of treatment 
depends on the hepatitis C virus genotype. For HCV 
genotype 1 or 4, patients should be treated for 48 weeks. 
For HCV genotype 2 or 3, treatment duration is 24 weeks 
(Sherman et al., 2007; Lagging et al., 2009; Maieron et 
al., 2010; Nice, 2010).
In the German context, to prevent one clinical event 
such as progression to cirrhosis, descompensated cirrhosis, 
hepatocellular carcinoma, liver transplantation and death 
due to liver failure during 20 years, the numbers needed 
to treat were approximately 3 for IFN plus RBV and 2 for 
PEG plus RBV, when compared with no antiviral therapy. 
Compared to no antiviral therapy, IFN plus RBV saved 2.9 
life years, and PEG plus RBV saved 4.6 life years (Siebert 
et al., 2005).
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Differences in countries’ sociodemographic 
structure, distribution of patients’ clinical characteristics, 
patients’ preferences, resource utilization and prices make 
it difficult, if not impossible, to transfer the results from 
other health care systems to the Brazilian reality (Siebert 
et al., 2003; Vanni et al., 2009).
The combination therapy with PEG is more 
expensive than IFN (Siebert et al., 2003). The use of 
PEG in the replacement of IFN is limited due to its high 
cost. In Brazil, the option has been to limit the use of this 
medicine to subjects with genotype 1 or co-infection with 
HIV(Brasil, 2007).
The aim of this study is to compare the cost and 
effectiveness for patients with genotype 2 or 3 of PEG as 
the first choice of treatment with what is suggested in the 
Brazilian guidelines.
METHODS
We developed a decision analysis Markov model to 
examine the cost and effectiveness of chronic hepatitis C 
treatment in patients with genotype 2 or 3 from a public 
health system perspective in Brazil.
The Brazilian guidelines recommend to patients with 
genotype 2 or 3 without cirrhosis (F4) or F3 Metavir score 
the use of IFN plus RBV for 24 weeks and, subsequently 
for non-responders and relapsers, PEG plus RBV for 48 
weeks (PEG-SEC). We compared this course of treatment 
with the use of PEG as a first choice of treatment for 24 
weeks (PEG-FIRST24).
The SVR rates were taken from meta-analysis 
conducted on the Brazilian population and according to 
the group undergoing treatment (Blatt, 2011).
The cost data were from a Brazilian micro costing 
study from a public health perspective. The costs include 
treatment cost for antiviral drugs, secondary medicines, 
diagnostic tests, outpatient visits to physicians and 
other professionals, hospitalizations, nursing and 
pharmaceutical care (Blatt, 2011).
The outcome measures were SVR, direct costs and 
incremental cost effectiveness ratio (ICER). The cost-
effectiveness analysis compares the costs and clinical 
outcomes. The ICER represents the additional cost and 
effectiveness obtained, when one alternative is more 
effective and also more expensive.
The role of the sensitivity analysis is to test the 
variation of SVR and costs. The decision model was done 
using TreeAge Pro 2011 software.
RESULTS
A systematic review of eight Brazilian studies 
evaluated 486 non-HIV naïve patients with HCV genotype 
2 or 3 who underwent treatment with IFN plus RBV for 
24 weeks. The pooled response rate was 54.3% (95% CI 
39.3-69.3) (Blatt, 2011).
Patients who were genotype 2 or 3, without HIV, 
who underwent treatment with PEG plus RBV for 48 
weeks were the focus of two studies (n=81) and the pooled 
response rate was 73.2% (95% CI 63.6-82.8). The relapsed 
patients who were genotype 2 or 3 had a pooled response 
rate (n=17) of 59.0% (95% CI 32.9-85.1). Among non-
responder patients who were genotype 2 or 3 (n=79) the 
response rate was 50.2% (95% CI 33.4-67.0) (Blatt, 2011).
The total direct costs of hepatitis C treatment with 
IFN plus RBV is USD $ 982.25, with PEG 2a 180 mg plus 
RBV is USD $ 10,658.08 and with PEG 2b 120 mg plus 
RBV is USD $ 12,597.63. Antiviral drugs are the most 
expensive category of the cost of treatment, accounting 
for more than 40% of medical costs for IFN therapy and 
more than 88% for PEG therapy (Blatt, 2011).
The costs and effectiveness per course of treatment 
are included in our cost effectiveness analysis shown in 
Table I.
Model building for cost effectiveness analyses are 
shown in Figure 1. According to Brazilian data and from a 
public health perspective, with SVR of 87.8% and costs of 
USD $ 8,338.27, PEG-FIRST was more efective and more 
costly than PEG-SEC (SVR: 79.2%, costs: USD 5,852.99).
In the sensitivity analysis, for PEG-SEC dominates 
PEG-FIRST24 when SVR with IFN was less than 30%. 
On the other hand, when SVR with IFN was more then 
75%, PEG-SEC is dominant (SVR=88.2% and costs USD 
$ 3,753.00). PEG-SEC is also dominant when SVR to 
TABLE I - Costs (USD $) and effectiveness per course of treatment
Group Costs SVR (%)
Naive IFN + RBV 24 weeks 982.25 54.3
Naive PEG + RBV 24 weeks 5481.90 73.2
Relapser and nonreponder (IFN) + PEG + RBV 48 weeks 982.25 + 10,658.08 54.6
Relapser and nonreponder (PEG24) + PEG + RBV 48 weeks 5481.90 + 10,658.08 54.6
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PEG24 weeks was less than 54%. ICER for PEG-FIRST24 
is USD $28,963.86 per additional SVR.
DISCUSSION
Hepatitis C treatment has the potential to prevent 
clinical events such as progression to cirrhosis, 
decompensated cirrhosis, hepatocellular carcinoma, liver 
transplantation and death due to liver failure. Therefore, 
the use of best practice could prevent side effects and 
waste of resources.
The most common side effects with a combination 
of PEG and RBV include injection site reactions, 
influenza-like symptoms (fatigue, headache, fever, 
rigors, and myalgia), psychiatric side effects (depression, 
irritability, anxiety and insomnia), nausea, alopecia, skin 
reactions (rash, pruritis and dry skin), plaquetopenia, 
neutropenia and anemia. This side effect profile often 
makes therapy difficult to tolerate and sometimes requires 
dose modifications and/or additional medical treatments 
(Fried, 2002; Mchutchison, Manns, Longo, 2006; 
Mchutchinson et al., 2007).
Severe side effects may occur more frequently in 
patients treated with PEG plus RBV than in patients treated 
with IFN plus RBV (Manns et al., 2001; Fried et al., 2002). 
From this point of view the best choice is PEG-SEC. 
FIGURE 1 - Cost effectiveness analysis comparing PEG-SEC with PEG-FIRST24.
FIGURE 2 - Results of cost effectiveness analysis comparing PEG-SEC with PEG-FIRST24.
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However, if SVR rates to IFN are lower, a great number 
of patients will undergo re-treatment with PEG.
Re-treatment with PEG plus RBV may be offered 
to people whose hepatitis C has not shown an adequate 
response to treatment (non-response) or has responded 
but subsequently relapsed. On the other hand, for patients 
who were not successful with IFN to undergo a new course 
of treatment could decrease the quality of their lives and 
expose them to side effects again.
In clinical trials, as mentioned above, when 
PEG alfa-2b and IFN alfa-2b combination therapies 
were compared for patients with genotype 2 or 3, SVR 
don’t have statistical difference significant (Manns, 
Mchutchison et al., 2001). In a meta-analysis of real life 
Brazilian studies the values were similar to PEG and 
smaller to IFN (Blatt, 2011) respectively.
SVR rates in individual studies in Brasil to Non-HIV 
naïve patients with HCV genotype 2 or 3 who underwent 
treatment with IFN plus RBV for 24 weeks varied from 
33% to 80% (Alves, De Azevedo et al., 2003; Acras, 
Pedroso et al., 2004; Borges, 2004; Villela-Nogueira, 
Perez et al., 2005; Parise, De Oliveira et al., 2006; Fachini, 
2008; Almeida et al., 2009; Carneiro et al., 2010; Vigani et 
al., 2012). SVR rates from this Brazilian studies are very 
different from each other and below the main clinical trials 
found in literature (Manns et al., 2001). In this respect, it 
is important to emphasize that this is a follow-up study of 
patients treated in a real life scenario of Brazilian public 
health system, reflecting the reality of our health care system 
and regions differences. Also, patients are different from 
the reality of a clinical trial where the inclusion criteria are 
extremely strict and approach to patient is done differently.
These data showed that in real life in Brazil SVR 
to IFN therapy was lower in comparison to clinical trials. 
One possible reason for this is that according to current 
Brazilian guidelines PEG is administered once a week, 
in specialized centers, so the vials that should be stored 
at 2-8 oC have been stored in an appropriate environment 
under pharmaceutical supervision. However, the IFN vials, 
which are administered three times a week, are stored in 
patients’ houses without temperature control.
In other hand, since 2000, biosimilar standard IFN 
has been used in Brazil for genotypes 2 or 3 infections. 
Biosimilar Peg-IFN is not available, the only Peg- IFN 
formulations currently available are Peg- ifn alpha-2a 
(Pegasys ®) or alpha-2b (Peg i ntron®). Therefore, the 
Peg- IFN used in this study are the same formulations 
used in studies reported in the literature (Vigani, 2012). 
Therefore, this authors suggests that biosimilar IFN in 
Brasil have less effectiveness than the main clinical trials 
found in literature.
In addition to the issue of storage, and despite lower 
rates of SVR to IFN therapy, patients that are followed 
up in specialized centers probably have more chance 
of concluding treatment compared to patients who took 
medicines at home.
PEG-FIRST24 has a convenient dosage schedule 
compared to IFN therapy (once a week rather than three 
times a week). Moreover, discontinuation of treatment is 
most common in patients who received treatment for 48 
weeks compared to those who received treatment for 24 
weeks (Shepherd et al., 2004). In patients infected with 
HCV genotype 2 or 3 the rates of SVR achieved after 24 
weeks of treatment were not increased by prolonging 
treatment for a further 24 weeks (Nice, 2010), therefore, 
treatment with PEG-FIRST24 has the same SVR and is 
less costly. Effective patient education and drug therapy 
management are essential in enabling patients to adhere 
to the treatment regimen, which lasts for either 24 or 
48 weeks. Frequent monitoring of patients and, often, 
adjustments in the dosage of one or both components of 
the therapy are necessary during the course of treatment 
(Olson, Lentz, 2009).
This study has some limitations, firstly in Brazil 
the SVR rates can be different according to service 
organization and secondly we assume that 100% who 
failed the first treatment will undergo the second treatment.
Therefore, study done with Brazilian population 
suggest that subjects with chronic hepatitis due to HCV 
genotypes 2 or 3 and who have a low degree of fibrosis are 
ideal candidates for treatment with IFN plus RBV. On the 
other hand, patients with advanced stage fibrosis had low 
rates of response to this combined therapy, and a criterion 
of treatment with pegylated interferon as a first alternative 
should be considered (Parise et al., 2006). Despite this 
considerations we don’t do sub analysis considering the 
degree of hepatic fibrosis.
CONCLUSION
In the Brazilian context, PEG-FIRST24 is more 
effective and more costly than PEG-SEC. Start to therapy 
with IFN could be dominant only when rates of IFN therapy 
are higher than 75% or when rates of PEG24 therapy are 
lower than 54%. For this option of treatment monitored the 
biosimilar IFN effectiviness are very important.
Effectiveness or cost-effectiveness cannot be 
automatically inferred from these results without 
additional decision analyses. Regardless of the antiviral 
therapy chosen we need to improve the patient care on 
treatment. Improve the IFN effectiveness could be a good 
option for better results to hepatitis C treatment.
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Considering the lower rates of successful treatment 
with IFN from Brazilian studies the results suggest 
more effetivenes with PEG treatment to non-HIV naïve 
patients with HCV genotype 2 or 3, however PEG have 
incremental costs when compare with IFN.
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